Skip to main content
. 2019 May 15;18(1):802–816. doi: 10.3892/etm.2019.7579

Figure 3.

Figure 3.

Forest plots for the meta-analysis on the efficacy and safety of NAC therapy for idiopathic pulmonary fibrosis (IPF) with regard to the secondary outcomes. (A) DLCO; (B) DLCO%; (C) VC; (D) PaO2; (E) 6MWT; (F) mortality. DLCO, diffusing capacity for carbon monoxide; DLCO%, percentage predicted DLCO; VC, vital capacity; PaO2, partial arterial oxygen pressure; 6MWT, 6-minute walking distance test; IV, inverse variance; Std., standard; M-H, Mantel-Haenszel; NAC, N-acetylcysteine; df, degrees of freedom.